替格瑞洛联合阿司匹林在急性缺血性卒中或短暂性脑缺血发作中的获益与风险时间进程
THALES试验的探索性分析纳入11016例轻中度缺血性卒中或高危TIA患者,评估30天治疗期内替格瑞洛联合阿司匹林与单用阿司匹林相比的累积疗效和安全性结局。结果显示,替格瑞洛联合阿司匹林在第一周即减少主要缺血事件,且大出血风险增加约0.3%,净临床影响在第一周即有利于替格瑞洛联合阿司匹林并维持30天。
要点
- 替格瑞洛联合阿司匹林在第一周减少主要缺血事件(4.1% vs 5.3%,绝对风险降低1.15%,95%CI 0.36%-1.94%)。
- 大出血风险在第一周增加,绝对风险增加约0.3%,随后几周保持相对恒定。
- 净临床影响在第一周即有利于替格瑞洛联合阿司匹林(绝对风险降低0.97%,95%CI 0.17%-1.77%),并维持30天。
核心结论
- 在轻中度缺血性卒中或高危TIA患者中,替格瑞洛联合阿司匹林的治疗效应从第一周即出现。
- 替格瑞洛联合阿司匹林的缺血获益在整个治疗期内超过大出血风险。
- 该结果可能支持在这些患者中使用替格瑞洛联合阿司匹林治疗30天。
研究设计与样本
- THALES试验的探索性分析。
- 共纳入11016例患者,替格瑞洛联合阿司匹林组5523例,阿司匹林组5493例,平均年龄65岁,女性占39%。
- 评估30天治疗期内不同时间点的不可逆疗效和安全性结局的累积发生率。
主要发现
- 主要缺血事件(缺血性卒中或非出血性死亡的复合终点)的降低出现在第一周(4.1% vs 5.3%;绝对风险降低1.15%,95%CI 0.36%-1.94%),并持续整个30天治疗期。
- 大出血(颅内出血和致命性出血的复合终点)在第一周增加,随后几周保持相对恒定(绝对风险增加约0.3%)。
- 累积分析显示,净临床影响在第一周有利于替格瑞洛联合阿司匹林(绝对风险降低0.97%,95%CI 0.17%-1.77%),并在30天内保持恒定。
关键数值与推荐
- 主要缺血事件定义:缺血性卒中或非出血性死亡的复合终点。
- 大出血定义:颅内出血和致命性出血的复合终点。
- 净临床影响定义:上述两个终点的组合。
临床怎么用
- 作者认为,在轻中度缺血性卒中或高危TIA患者中,替格瑞洛联合阿司匹林的缺血获益在整个治疗期内超过大出血风险,可能支持使用30天替格瑞洛联合阿司匹林治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial. METHODS: In an exploratory analysis of the THALES trial, we evaluated the cumulative incidence of irreversible efficacy and safety outcomes at different time points during the 30-day treatment period. The efficacy outcome was major ischemic events defined as a composite of ischemic stroke or nonhemorrhagic death. The safety outcome was major hemorrhage defined as a composite of intracranial hemorrhage and fatal bleedings. Net clinical impact was defined as the combination of these 2 endpoints. RESULTS: This analysis included a total of 11,016 patients (5,523 in the ticagrelor-aspirin group, 5,493 in the aspirin group) with a mean age of 65 years, and 39% were women. The reduction of major ischemic events by ticagrelor occurred in the first week (4.1% vs 5.3%; absolute risk reduction 1.15%, 95% CI 0.36%-1.94%) and remained throughout the 30-day treatment period. An increase in major hemorrhage was seen during the first week and remained relatively constant in the following weeks (absolute risk increase ≈0.3%). Cumulative analysis showed that the net clinical impact favored ticagrelor-aspirin in the first week (absolute risk reduction 0.97%, 95% CI, 0.17%-1.77%) and remained constant throughout the 30 days. DISCUSSION: In patients with mild-moderate ischemic stroke or high-risk TIA, the treatment effect of ticagrelor-aspirin was present from the first week. The ischemic benefit of ticagrelor-aspirin outweighs the risk of major hemorrhage throughout the treatment period, which may support the use of 30-day treatment with ticagrelor and aspirin in these patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for patients with mild-moderate ischemic stroke or high-risk TIA, the ischemic benefit of ticagrelor-aspirin outweighs the risk of major hemorrhage throughout the 30-day treatment period.
引用
- Wang Y, Pan Y, Li H, et al. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology. 2022. PMID: 35437261. doi:10.1212/WNL.0000000000200355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。